Avid Bioservices

Avid Bioservices, Inc. engages in the commercial manufacturing. The firm focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Avid Bioservices Achieves Record Revenues, Faces Margin Challenges

Avid Bioservices achieved record revenues and strong bookings, but faced challenges with decreased gross margins and increased expenses. Moving into the viral vector space and with a strong late-phase project pipeline, the company sees opportunities for growth in the next 12 to 15 months.

Avid Bioservices reports Q2 earnings, focuses on expansion and innovation

Avid Bioservices showcased positive operational performance with increased utilization of the new mammalian line fleet and a record backlog. While facing challenges related to net loss and revenue recognition delays, the company remains focused on expansion and innovation, presenting opportunities for growth in the cell and gene therapy space and later-stage products.

Avid Bioservices reports robust Q3 earnings and targets pharma growth

Avid Bioservices delivered strong financial results in Q3 2023, showcasing revenue growth and operational efficiency.
While facing challenges in margins and expenses, the company's strategic focus on quality and growth presents opportunities for expansion.
With a solid cash position, record backlog, and targeted business development, Avid is poised for continued success in the market.

Avid Bioservices reports record revenues and backlog, eyes strategic growth

Avid Bioservices delivered a strong performance in Q4 2023, marked by record revenues and backlog, showcasing operational efficiency and market demand.
While facing challenges such as margin impact and resource allocation shifts, the company remains optimistic about its growth prospects and revenue stability.
Strategic opportunities lie in leveraging the strong backlog, cash flow, and planned CapEx to drive future growth and operational excellence.

Avid Bioservices reports revenue growth and expansion plans for 2024

Avid Bioservices' Q1 2024 performance reflects revenue growth and strategic investments in expanding capacity and capabilities.
While facing challenges in gross margins and profitability, the company's progress on the new facility signals future growth potential.
Opportunities lie in leveraging the completed facility to drive revenue, enhance market competitiveness, and address analyst concerns for improved performance.

Avid Bioservices reports record backlog and growth opportunities for 2024

Avid Bioservices showcased financial resilience with an improved cash position and strong backlog, despite facing revenue challenges. The company's focus on new services, customer diversity, and operational efficiency bodes well for future growth.

Avid Bioservices reports revenue growth and strategic expansions in Q3

Avid Bioservices reported strong revenue growth and backlog performance in Q3, while facing revenue decline and cost challenges compared to the previous year. Strategic expansions and operational refinements position the company for future opportunities in a competitive market landscape.

Avid Bioservices reports revenue growth and new projects, faces cost challenges

Avid Bioservices reported positive revenue growth and secured new project agreements, positioning the company for future expansion.
Despite challenges such as increased SG&A expenses and a net loss, Avid's focus on capacity utilization and new programs offers growth potential.
Addressing operational challenges and uncertainties while capitalizing on opportunities can drive Avid Bioservices towards improved financial performance.
The company's financial stability, strong backlog, and focus on profitability highlight a resilient business strategy amidst industry dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avid Bioservices, Inc. engages in clinical and commercial manufacturing of biologics. It focuses on the biopharmaceutical products derived from mammalian cell culture for culture for biotechnology and pharmaceutical companies. It specializes in clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory submissions and support. The company was founded on June 3, 1981 and is headquartered in Tustin, CA.

TUSTIN, Calif., Sept.  15, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) solely by means of remote communication (i.e., a virtual-only stockholder meeting). This change is to protect the safety, health and well-being of its stockholders, directors, employees and the public during the COVID-19 pandemic. As previously announced, the Annual Meeting will be held on Tuesday, October 20, 2020 at 10:00 a.m. PDT.

Avid Bioservices Announces Move to Virtual-Only Annual Meeting of Stockholders on October 20, 2020

TUSTIN, Calif., Sept.  10, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the 18th Annual Morgan Stanley Global Healthcare Conference.  The conference, which will take place September 14-18, 2020, is being conducted with a virtual format.

Avid Bioservices to Participate in 18th Annual Morgan Stanley Global Healthcare Conference

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q1 2021 Results - Earnings Call Transcript

Shares of Avid Bioservices (NASDAQ:CDMO) rose 6.81% after the company reported Q1 results.

Recap: Avid Bioservices Q1 Earnings

-- Recorded First Quarter Revenue of $25.4 Million --   -- S igned Three New Customers and Project Expansion Orders with Current Customers for $20 Million  --

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2020 and Recent Developments

TUSTIN, Calif., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Mapp Biopharmaceutical, Inc., has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.

Avid Bioservices Selected by Mapp Biopharmaceutical, Inc. for Clinical Development of Novel Human Monoclonal Antiviral Antibody

TUSTIN, Calif., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2021 on September 1, 2020 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).  Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments.

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2021 After Market Close on September 1, 2020

TUSTIN, Calif., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that Iovance Biotherapeutics (NASDAQ: IOVA) has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.

Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics Argonaut’s Clinical Fill-Finish Capabilities to Complement Avid’s Upstream and Downstream Process Development and Biologics Manufacturing Services in Supporting Developers of Biologic Therapeutics

Avid Bioservices and Argonaut Manufacturing Services Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Process Development, Drug Substance Manufacturing and Drug Product Parenteral Manufacturing

Avid Bioservices (CDMO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Avid Bioservices (CDMO) Catches Eye: Stock Jumps 5.4%

The company still had significant production problems. But it also picked up a lot of new business in Q4.

How Avid Bioservices Beat Wall Street Estimates in Q4

Investors need to pay close attention to Avid Bioservices (CDMO) stock based on the movements in the options market lately.

Implied Volatility Surging for Avid Bioservices (CDMO) Stock Options

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q4 2020 Results - Earnings Call Transcript

-- Appointed Nicholas Green as President and Chief Executive Officer --   -- Recorded Fourth Quarter Revenue of $12.6 Million and Annual Revenue of $59.7 Million --

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2020 and Recent Developments

Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion Seasoned Executive Brings More than 30 Years of Pharmaceutical and Healthcare Services Industry Experience to Lead Avid Through Next Phase of Growth and Expansion

Avid Bioservices Names Nicholas Green as President and Chief Executive Officer

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Avid Bioservices (CDMO) to Report a Decline in Earnings: What to Look Out for

Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances Full Service “Sequence-to-Manufacturing” Offering Designed to Drive Efficiencies and Reduce Overall Timelines for Delivering Early-Stage CGMP Bulk Drug Substances

Avid Bioservices and Aragen Bioscience Enter Agreement to Offer Biotechnology and Pharmaceutical Clients Integrated Solution for Cell Line and Process Development through Commercial Manufacturing

Enphase Energy

These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.

2 High-Risk, High-Reward Stocks to Add to Your Watch List

TUSTIN, Calif., April  13, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of two senior directors of business development with responsibility for driving CDMO business growth within North America, Europe and Asia.  Jason C. Brady, Ph.D. will serve as senior director of business development for the eastern region of North America, as well as Europe.  Sylvia Hinds has been named senior director of business development for the western region of North America in addition to the Asia Pacific region.

Avid Bioservices Announces Appointment of Two Senior Directors of Business Development with Responsibility for North America, Europe and Asia

Company Honored for Capabilities, Expertise, Reliability, Compatibility, and Service in the Contract Development and Manufacturing Industry

Avid Bioservices Receives Five 2020 CMO Leadership Awards

The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.

Here's Why Avid Bioservices Tumbled Today

Avid Bioservices, Inc. (CDMO) CEO Richard Hancock on Q3 2020 Results - Earnings Call Transcript

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (CDMO) Reports Q3 Loss, Misses Revenue Estimates

Avid Bioservices (NASDAQ:CDMO) reported Q3 results. Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.

Recap: Avid Bioservices Q3 Earnings

TUSTIN, Calif., March  04, 2020  (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").

News for Avid Bioservices Stock (CDMO)